SGEN US81181C1045

Report

Delayed Nasdaq - 04:00 2022-07-01 pm EDT
180.11	USD		+1.79%

07/02	Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer	BU
07/02	Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA in Combination with Trastuzumab	CI
07/01	INSIDER SELL : Seagen	MT

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

06/27/2022	06/28/2022	06/29/2022	06/30/2022	07/01/2022	Date
177.73(c)	178.47(c)	179.06(c)	176.94(c)	180.11(c)	Last
1 192 439	1 468 981	1 150 018	1 232 598	958 533	Volume
-0.89%	+0.42%	+0.33%	-1.18%	+1.79%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2022	1 787 M - -
Net income 2022	-653 M - -
Net cash position 2022	1 615 M - -
P/E ratio 2022	-52,0x
Yield 2022	-

Sales 2023	2 480 M - -
Net income 2023	-221 M - -
Net cash position 2023	1 835 M - -
P/E ratio 2023	-147x
Yield 2023	-

Capitalization	33 154 M 33 154 M -
EV / Sales 2022	17,7x
EV / Sales 2023	12,6x
Nbr of Employees	2 675
Free-Float	99,2%

More Financials

Company

Seagen Inc. specializes in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows: - product sales (88%); - royalties (9.6%); - licenses and collaboration agreements (2.4%).

Sector

Biotechnology & Medical Research

Calendar

07/28

Earnings Release

More about the company

Ratings of Seagen Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about SEAGEN INC.

07/02	Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meanin..	BU
07/02	Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Sh..	CI
07/01	INSIDER SELL : Seagen	MT
06/29	Raymond James Starts Seagen at Outperform With $220 Price Target	MT
06/24	BMO Capital Starts Seagen at Market Perform With $169 Price Target	MT
06/24	SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 3000 Value Index	CI
06/24	SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell Midcap Value Index	CI
06/24	SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 3000E Value Index	CI
06/24	SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell Small Cap Comp Value Index	CI
06/24	SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 1000 Value Index	CI
06/23	Merck Reportedly Pushes Forward with Potential Deal for Seagen	CI
06/21	Oppenheimer Adjusts Seagen Price Target to $208 From $160, Maintains Outperform Rating	MT
06/17	US Stocks Mixed on Friday as Fed's Powell Reiterates Focus on Containing Inflation	MT
06/17	US Stocks Mixed on Friday as Powell Reiterates Focus on Containing Inflation	MT
06/17	Adobe, Devon Energy fall; Moderna, Seagen rise	AQ

More news

News in other languages on SEAGEN INC.

07/02	Seagen Inc. annonce les résultats complets de l'essai pivot de phase 2 MOUNTAINEER, qui..
06/24	Wall Street finit en hausse, moins anxieuse d'une récession et de l'inflation
06/24	MÄRKTE USA/Börsen kräftig rauf - Hoffnung auf weniger harsche Fed
06/24	Wall Street positief richting weekend
06/24	Wall Street koerst flink hoger

More news

Analyst Recommendations on SEAGEN INC.

06/29	Raymond James Starts Seagen at Outperform With $220 Price Target	MT
06/24	BMO Capital Starts Seagen at Market Perform With $169 Price Target	MT
06/21	Oppenheimer Adjusts Seagen Price Target to $208 From $160, Maintains Outperform Rating	MT

More recommendations

Provided by Scoopnest.com

Analysis

Merck considering purchase of cancer drug maker Seagen - WSJ